GEN Exclusives

More »

GEN News Highlights

More »
Feb 5, 2007

Stratagene Gains Rights to over 150 microRNA Sequences

  • Stratagene obtained the last of the four co-exclusive licenses to more than 150 microRNA sequences available from Max Planck Innovation, the technology transfer agency of the Max Planck Society.

    "The potential of these sequences, when paired with our proprietary FullVelocity technology, should allow us to develop important detection tests for the molecular diagnostics marketplace," says Joseph A. Sorge, M.D., chairman and CEO.

    Under the terms of the agreement, Stratagene will have the right to use the microRNA sequences for the development, manufacture, and sale of molecular diagnostic kits. Stratagene reports that it is particularly interested in the association of microRNAs with cancer.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Children and Antipsychotic Drugs

Do you think children and adolescents with behavioral problems are overmedicated?